Advanced AMD Monitoring Using OCT-A

OCT-A enables precise, long-term monitoring of non-exudative macular neovascularization in AMD.

By: Damon Dierker, OD, FAAO

Optometric Management November 6, 2025

5 Key Takeaways

1

OCT-A allows for precise monitoring of non-exudative macular neovascularization in age-related macular degeneration (AMD).
2

A 75-year-old female patient with intermediate AMD showed stable visual acuity and no signs of exudation during her evaluation.
3

The presence of non-exudative macular neovascularization is a significant risk factor for future exudation, necessitating close monitoring.
4

Observation is the recommended strategy for non-exudative MNV, with anti-VEGF therapy reserved for cases with exudation.
5

Frequent monitoring is essential, especially after detecting new non-exudative lesions, to prevent progression to exudative stages.

Damon Dierker

Bio: Damon Dierker, OD, FAAO, is an optometrist whose clinical work and writing focus on dry eye disease and ocular surface disease in an OD-MD multispecialty practice setting. He has described practical approaches to screening patients for dry eye disease during comprehensive eye examinations, cataract and refractive evaluations, and ocular surface disease-focused visits. His published clinical commentary emphasizes efficient dry eye testing protocols, including symptom questionnaires such as OSDI, SPEED, and DEQ-5, along with ocular surface staining and tear breakup time to help identify patients who may need treatment without disrupting clinic flow.

PentaVision

Optometric Management

Advanced AMD Monitoring Using OCT-A

5 Key Takeaways

1

2

3

4

5

Recommendations